Journal
CLINICAL AND EXPERIMENTAL DERMATOLOGY
Volume 33, Issue 5, Pages 551-554Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2230.2008.02976.x
Keywords
-
Categories
Funding
- Medical Research Council [G0500449] Funding Source: Medline
- MRC [G0500449] Funding Source: UKRI
Ask authors/readers for more resources
Methotrexate's traditional role as a first line agent for moderate to severe psoriasis is being challenged by the rapid and growing use of biological therapies. A recent study comparing adalimumab with methotrexate showed significantly superior efficacy of adalimumab over methotrexate over 16 weeks. Although it is inexpensive, the future use of methotrexate may be compromised by its unpredictable response and toxicity, and by the introduction of newer, more effective biological therapies. However, recent advances in the screening of liver fibrosis by monitoring serum levels of the aminoterminal peptide fragment of type III procollagen have reduced the need for liver biopsy. Furthermore, the potential for personalized methotrexate use by application of modern pharmacogenetics and pharmacokinetics may ensure its place as a first-line agent for the treatment of psoriasis for the foreseeable future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available